Bacille-Calmette-Guerin non-responders: how to manage

Intravesical immunotherapy with bacille-Calmette-Guerin (BCG) is indicated in the treatment of high-risk and intermediate-risk non-muscle invasive bladder cancer (NMIBC). Our goal is to describe the various disease states following induction and maintenance BCG and to describe contemporary treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: von Rundstedt, Friedrich-Carl, Lerner, Seth P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2015
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708234/
https://www.ncbi.nlm.nih.gov/pubmed/26816828
http://dx.doi.org/10.3978/j.issn.2223-4683.2015.05.03
_version_ 1782409426762727424
author von Rundstedt, Friedrich-Carl
Lerner, Seth P.
author_facet von Rundstedt, Friedrich-Carl
Lerner, Seth P.
author_sort von Rundstedt, Friedrich-Carl
collection PubMed
description Intravesical immunotherapy with bacille-Calmette-Guerin (BCG) is indicated in the treatment of high-risk and intermediate-risk non-muscle invasive bladder cancer (NMIBC). Our goal is to describe the various disease states following induction and maintenance BCG and to describe contemporary treatment options and the current and projected clinical trial landscape for patients who recur following BCG therapy.
format Online
Article
Text
id pubmed-4708234
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-47082342016-01-26 Bacille-Calmette-Guerin non-responders: how to manage von Rundstedt, Friedrich-Carl Lerner, Seth P. Transl Androl Urol Review Article Intravesical immunotherapy with bacille-Calmette-Guerin (BCG) is indicated in the treatment of high-risk and intermediate-risk non-muscle invasive bladder cancer (NMIBC). Our goal is to describe the various disease states following induction and maintenance BCG and to describe contemporary treatment options and the current and projected clinical trial landscape for patients who recur following BCG therapy. AME Publishing Company 2015-06 /pmc/articles/PMC4708234/ /pubmed/26816828 http://dx.doi.org/10.3978/j.issn.2223-4683.2015.05.03 Text en 2015 Translational Andrology and Urology. All rights reserved.
spellingShingle Review Article
von Rundstedt, Friedrich-Carl
Lerner, Seth P.
Bacille-Calmette-Guerin non-responders: how to manage
title Bacille-Calmette-Guerin non-responders: how to manage
title_full Bacille-Calmette-Guerin non-responders: how to manage
title_fullStr Bacille-Calmette-Guerin non-responders: how to manage
title_full_unstemmed Bacille-Calmette-Guerin non-responders: how to manage
title_short Bacille-Calmette-Guerin non-responders: how to manage
title_sort bacille-calmette-guerin non-responders: how to manage
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708234/
https://www.ncbi.nlm.nih.gov/pubmed/26816828
http://dx.doi.org/10.3978/j.issn.2223-4683.2015.05.03
work_keys_str_mv AT vonrundstedtfriedrichcarl bacillecalmetteguerinnonrespondershowtomanage
AT lernersethp bacillecalmetteguerinnonrespondershowtomanage

Ejemplares similares